You are here

Spatiotemporally Controlled Keratin Biomaterial Delivery System for Functional Tissue Regeneration Phase II

Award Information
Agency: Department of Defense
Branch: Defense Health Agency
Contract: W81XWH-11-C-0060
Agency Tracking Number: O2-1228
Amount: $999,999.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: OSD10-H03
Solicitation Number: 2010.3
Timeline
Solicitation Year: 2010
Award Year: 2012
Award Start Date (Proposal Award Date): 2012-03-29
Award End Date (Contract End Date): N/A
Small Business Information
Richard Dean Research Building, Suite 168 391 Technology Way
Winston-Salem, NC -
United States
DUNS: 827054219
HUBZone Owned: Yes
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Seth Tomblyn
 Principle Scientist
 (980) 989-0448
 seth.tomblyn@keranetics.com
Business Contact
 Kim Westmoreland
Title: Managing Director
Phone: (336) 918-6404
Email: kim.westmoreland@keranetics.com
Research Institution
 Stub
Abstract

Skeletal muscle injury is a significant challenge to warfighters due to the severity of the injuries often caused by Improvised Explosive Devices. Currently, there are few viable clinical treatment options for these types of injuries. Keratin hydrogels offer a solution to these challenges as carriers of cells and growth factors. Human epithelial keratins are the major structural proteins in cells and form a cytoplasmic network of intermediate filaments. Human hair keratins are genetically similar to epithelial keratins and their intrinsic characteristics make them unique candidates for biomaterial-based carriers of growth factors and cells. In the Phase I project, we showed that keratin hydrogels provide sustained release of growth factors and maintain cell viability in vivo. This Phase II proposal will build on these findings and move toward a product that facilitates skeletal muscle regeneration. The Phase II objectives are to optimize formulations of keratin for delivery of cells and supporting growth factors (FGF and IGF-1), to test the safety and immunogenicity of these formulations, and to assess the functional muscle recovery in two rodent models of muscle loss. Completion of the Phase II objectives will yield a keratin hydrogel formulation optimized for in vivo regeneration of injured skeletal muscle.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government